Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Core Insights - Foghorn Therapeutics Inc. is advancing its clinical-stage pipeline, particularly focusing on FHD-909, a selective SMARCA2 inhibitor, which is currently in Phase 1 trials targeting SMARCA4 mutated cancers, primarily non-small cell lung cancer (NSCLC) [1][2][5] Group 1: FHD-909 Program - FHD-909 demonstrates synergistic anti-tumor activity when combined with chemotherapy, KRAS inhibitors, and pembrolizumab, warranting further clinical exploration [1][4] - The ongoing Phase 1 trial of FHD-909 is evaluating patients with SMARCA4 mutations who have exhausted standard treatment options, with a focus on NSCLC and other advanced solid tumors [5][9] - Preclinical studies indicate that FHD-909 selectively inhibits SMARCA4 mutant cancer cells and shows robust anti-tumor efficacy in xenograft models [4][13] Group 2: Selective CBP and EP300 Degrader Programs - The Selective CBP degrader program shows promise in preclinical models, indicating potential benefits in solid tumors beyond EP300-mutant cancers [6][10] - Initial preclinical data for the Selective EP300 degrader program suggests significant anti-cancer activity in hematological malignancies, with ongoing characterization of its therapeutic potential [7][11] - The Selective ARID1B degrader program is also in development, targeting a synthetic lethal mechanism implicated in up to 5% of all solid tumors [8][16] Group 3: Upcoming Events and Presentations - Foghorn management will hold a virtual investor event on April 29, 2025, to discuss pipeline updates, including the FHD-909 program and other ongoing research efforts [2][12] - A poster presentation on the Selective EP300 degrader program is scheduled for April 30, 2025, at the AACR Annual Meeting [2][7]